Recent studies suggest that antifungal resistance in yeast isolates of veterinary origin may be an underdiagnosed threat. We tested a collection of 92 ascomycetous yeast isolates that were obtained in Spain from birds, mammals and insects for antifungal susceptibility. MICs to amphotericin B and azoles were low, and no resistant isolates were detected. Despite these results, and given the potential role of animals as reservoirs of resistant strains, continuous monitoring of antifungal susceptibility in the veterinary setting is recommended.
A cquired resistance to azoles in Candida spp. and a shift among human infections toward non-albicans Candida species with intrinsic decreased susceptibility to azoles are emerging threats (1) (2) (3) . In addition, severe infections caused by azole-resistant ascomycetous yeasts belonging to other genera are being increasingly reported (4, 5) . The extensive use of antifungals in medical institutions plays a major part in this changing epidemiology (2, 3) . In this context, antifungal susceptibility testing has become essential for effective patient management and resistance surveillance (3) .
The results of some recent studies of yeast collections of animal origin suggest that azole resistance is also relatively common among isolates from diverse host species and that even healthy individuals can serve as a reservoir of resistant strains (6) (7) (8) (9) (10) (11) (12) (13) . For example, Cordeiro et al. (10) found resistance rates of Ͼ45% for fluconazole and itraconazole, and a 37.5% rate of cross-resistance to both compounds, in a Brazilian collection of 64 Candida tropicalis isolates obtained from several animal species. Similarly, substantial resistance to fluconazole and itraconazole has been found among Candida isolates from healthy birds and manatees bred in captivity in Brazil (6, 11, 12) and from dolphins in a Japanese aquarium (13) . Unfortunately, antifungal susceptibility data for animal yeast isolates from other geographic regions are still scarce.
We recently reported a case of multiazole resistance acquisition by C. tropicalis after prolonged antifungal therapy in a dog with urinary tract infection (14) . However, the prevalence of antifungal-resistant yeasts in the veterinary setting remains underexplored in Spain, where susceptibility testing of animal isolates is still uncommon. In this study, we screened a collection of ascomycetous yeast isolates obtained in Spain from animal clinical samples for in vitro resistance to azoles and cross-resistance to other antifungal compounds.
A total of 92 yeast isolates from the culture collection of our research group (COVEMI, Department of Animal Health, Universidad Complutense de Madrid, Spain) were analyzed. Studied isolates had been recovered from 62 animals distributed as follows: 48 bird isolates from 37 different individuals (4 domestic, 33 wild); 40 mammal isolates from 21 individuals (8 dogs, 3 ruminants, 1 horse, and 9 zoo animals); and 4 insect isolates from 4 honey bees.
Species-level identification of isolates was performed by sequencing the D1 and D2 domains of the large subunit rRNA gene using primers NL-1 and NL-4 (15) . The GenBank nucleotide database was searched using BLAST (http://blast.ncbi.nlm.nih.gov /Blast.cgi) for sequence similarity with reference strains. As the targeted sequence had only limited resolution power to differentiate Candida parapsilosis from its sibling species, Candida metapsilosis and Candida orthopsilosis (16), we will refer to these from now on as C. parapsilosis species complex or C. parapsilosis sensu lato.
All isolates were stored at Ϫ80°C as cell suspensions in Sabouraud dextrose broth (bioMérieux, Marcy l'Etoile, France) supplemented with 25% glycerol (Panreac, Barcelona, Spain).
In vitro antifungal susceptibility testing was performed according to the Clinical and Laboratory Standards Institute guidelines for yeasts (17) . The antifungal agents (all purchased from SigmaAldrich, Madrid, Spain) and concentrations tested were as follows: amphotericin B (0.031 to 16 g/ml), fluconazole (0.031 to 64 g/ml), and itraconazole, ketoconazole, posaconazole, and voriconazole (0.002 to 16 g/ml). In most cases, assay plates were incubated at 35°C in a humid atmosphere and read macroscopically at 24 and 48 h. Due to poor growth at 35°C, all Candida zeylanoides and Candida apicola isolates and a single Debaryomyces isolate were tested at 32°C, and reading of results was then performed after 48 h and 72 h of incubation. In all cases, the endpoint for the MIC was the antifungal concentration that produced a complete (100%) inhibition of visual growth (for amphotericin B) or prominent inhibition of growth (Ն50% inhibition for the remaining antifungal agents) (17) . Isolates of Candida albicans, C. parapsilosis sensu lato, C. tropicalis, Candida krusei, and Candida guilliermondii were classified as susceptible or resistant to fluconazole, itraconazole, and/or voriconazole according to the species-specific clinical breakpoints (CBPs) included in the M27-S4 document (18, 19) . C. krusei ATCC 6258 and C. parapsilosis ATCC 22019 were used as quality control strains, and all isolates were tested at least twice on different days.
Molecular identification revealed that studied isolates belonged to the following ascomycetous species: C. albicans (n ϭ 32), C. tropicalis (n ϭ 19), C. parapsilosis species complex (n ϭ 15), C. zeylanoides (n ϭ 6), C. apicola (n ϭ 4), C. guilliermondii (n ϭ 4), Candida catenulata (n ϭ 2), C. krusei (n ϭ 1), Candida lipolytica (n ϭ 1), Debaryomyces sp. (n ϭ 1), Geotrichum candidum (n ϭ 1), Kazachstania heterogenica (n ϭ 3), and Pichia mexicana (n ϭ 3).
A summary of the results obtained from antifungal susceptibility testing is shown in Table 1 , and the complete results data set can be found in Table S1 in the supplemental material. In general, MICs to amphotericin B were low for most isolates (Յ2 g/ml), and there was little difference among yeast species (Table 1) . Azole MICs were generally more variable (i.e., broader ranges) and species dependent (Table 1) . For example, most C. albicans, C. parapsilosis sensu lato, C. guilliermondii, and C. tropicalis isolates and the single Debaryomyces isolate displayed fluconazole MICs of Յ1 g/ ml, whereas all C. apicola, C. catenulata, and Kazachstania heterogenica isolates, three out of six C. zeylanoides isolates, and C. krusei and Geotrichum candidum (one isolate each) were inhibited at fluconazole concentrations of Ն4 g/ml. No resistant isolates were detected for any species-antifungal combination for which a CBP is available.
The results found in this study are in clear contrast with those of previous reports that reveal alarmingly high rates of azole resistance among Candida strains of veterinary origin (6) (7) (8) (9) (10) (11) (12) (13) . Notably, 47.8% of our isolates were collected between 2008 and 2014, when the first reports of substantial prevalence of azole resistance among yeast isolates obtained from animals were being published. Given the high interlaboratory reproducibility of the reference broth microdilution method used for in vitro susceptibility testing (20) , local differences in antifungal use practices, different criteria for classification of isolates as susceptible or resistant (i.e., displaying relatively low or high MICs, respectively) in the absence of validated CBPs for most species-drug combinations, and/or sampling bias might explain this discrepancy.
A major limitation of this and previous studies on antifungal susceptibility of ascomycetous yeast isolates of animal origin (6-13) is the small sample size, especially compared with studies dealing with human isolates. Unfortunately, antifungal susceptibility testing is still very uncommon in the veterinary setting. Therefore, we believe that the data here reported provide a useful baseline for a future comparative study of antifungal drug susceptibility of yeast isolates from animals in Spain and other geographical regions. Furthermore, given the role of animals as potential sources of fungal infection for humans (21) , continuous effort for detection of antifungal-resistant strains of animal origin is also relevant for human health.
In conclusion, despite our recent report of multiazole resistance acquisition by C. tropicalis during the course of a clinical case (14) , the results of this study suggest that, in Spain, antifungal resistance might not be yet widespread among ascomycetous yeast isolates of veterinary origin. Nevertheless, as animals can act as reservoirs of resistant strains, continuous monitoring of antifungal susceptibility by validated methods is recommended. Nucleotide sequence accession numbers. The nucleotide sequences determined in this study were deposited in the GenBank database under accession numbers KT718055 to KT718117 and KX097923 to KX097951.
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